Symbol List Views
Stock Details
CHARTS
COMPANY NEWS
STOCK ANALYSIS
FUNDAMENTALS
HOLDINGS
Edit Symbol List
Symbol Lookup
ISPH: Stock Quote & Summary Data
0.4%
| Last Sale | |
| Change Net / % |
|
| Best Bid / Ask | |
| 1y Target Est: | $ 8.25 |
| Today's High / Low | / |
| Share Volume | |
| 50 Day Avg. Daily Volume | 555,844 |
| Previous Close | $ 5.02 |
| 52 Wk High / Low | $ 6.536 / $ 2.59 |
| Shares Outstanding | 82,271,000 |
| Market Value | $ 414,645,840 |
| P/E Ratio | NE |
| Forward P/E (1yr) | NE |
| Earnings Per Share | $ -0.80 |
| Annualized Dividend | N/A |
| Ex Dividend Date | N/A |
| Dividend Payment Date | N/A |
| Current Yield | N/A |
| Beta | 1.59 |
| NASDAQ Official Open Price: | $ 4.96 |
| Date of NASDAQ Official Open Price: | Nov. 20, 2009 |
| NASDAQ Official Close Price: | $ 5.04 |
| Date of NASDAQ Official Close Price: | Nov. 20, 2009 |
Intraday Chart |
| 5d | 1m | 6m | 12m | More Charting |
Have a Question About ISPH?
Ask your question about about Inspire Pharmaceuticals, Inc. (ISPH) by typing it in the box below. You'll get direct responses from other members of the NASDAQ Answers community!
Hot Topics in NASDAQ Answers
The most popular questions & answers in the
NASDAQ Answers Community:
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on discovering, developing and commercializing prescription pharmaceutical products for diseases in the ophthalmic and respiratory/allergy areas. Our goal is to build and commercialize a sustainable pipeline of innovative new treatments based upon our technical and scientific expertise. Our portfolio of products and product candidates include: PRODUCTS AND THERAPEUTIC AREA/ COLLABORATIVE CURRENT STATUS IN PRODUCT CANDIDATES INDICATION PARTNER (1) THE UNITED STATES Products AzaSite® Bacterial InSite Vision Promoting conjunctivitis Elestat® Allergic ... More ...
Links to all Inspire Pharmaceuticals, Inc. (ISPH) Pages
Stock Analysis
Fundamentals
Holdings/Ownership
Company News for ISPH |
||
|
Inspire Reports Third Quarter 2009 Financial Results - Business Wire 11/05/2009 7:00AM |
||
|
Inspire Completes Patient Enrollment in Three Late-Stage Clinical Trials in Cystic Fibrosis, Dry Eye and Blepharitis - Business Wire 11/04/2009 7:00AM |
||
|
RothmanResearch.com Undertakes Study of JBLU, ADSK, ISPH, ARBA, DPTR and ALTR - Market Wire 11/03/2009 5:57AM |
||
|
BenchmarkJournal.com Free Analyst Review for QTM, MAT, PMCS, DTV, PETM and ISPH - Market Wire 10/29/2009 6:31AM |
||
|
AMZN, EWBC, KLIC, MENT, ISPH and JASO Receiving Professional Financial Coverage from RothmanResearch.com - Market Wire 10/23/2009 7:19AM |
||
|
Inspire Announces Date for Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results - Business Wire 10/22/2009 7:00AM |
||
|
Inspire's President and CEO Christy Shaffer Receives Cystic Fibrosis Foundation's Highest Award - Business Wire 10/20/2009 9:00AM |
Consensus Recommendation |
|
Analyst Info |
|
| Annual EPS Est: | $ -0.70 |
| Quarterly EPS Est: | $ -0.11 |
| PEG Ratio: | N/A |
| Mean Recommendation: View Summary/View All |
2.00 |
